Belgium· BE-AMP-SAM434454-00
Lyxumia 10 µg
A lixisenatide product containing lixisenatide, registered in Belgium by Sanofi-Aventis Groupe. The same ATC class is registered in 5 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lixisenatide is registered in 5 of 19 countries.
Countries holding a registration under ATC A10BJ03 (lixisenatide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 3 of them publish a price we can compare per daily dose
Lixisenatide · ATC A10BJ03
5 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Polandprice
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lixisenatide
- Manufacturer
- Sanofi-Aventis Groupe
- Country
- Belgium (BE)
- ATC code
- A10BJ03
- ATC class
- Lixisenatide
- Defined daily dose
- 20 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb3017423
- be_apb7705700
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
304 interactions on record for lixisenatide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lixisenatide · interactions on record
304 records
- 3 severe
- 259 moderate
- 42 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lixisenatide in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/299931f2-f1b9-4efd-bb88-6502248a9d7c GET /v1/drugs/299931f2-f1b9-4efd-bb88-6502248a9d7c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "REVOKED",
"name_en": "Lyxumia 10 µg",
"name_fr": "Lyxumia 10 µg",
"name_nl": "Lyxumia 10 µg",
"amp_code": "SAM434454-00",
"strengths": [
"10.0000",
"10.0000"
],
"pack_count": 1,
"substances": [
"Lixisenatide",
"Glycerol 85%",
"Sodium Acetate Trihydrate",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Lixisenatide",
"authorisation_numbers": [
"EU/1/12/811/001"
]
}See everything about lixisenatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.